Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Diseases of the Colon & Rectum
Erschienen in: Diseases of the Colon & Rectum 3/2007

01.03.2007 | Current Status

Serotonin and Its Role in Colonic Function and in Gastrointestinal Disorders

verfasst von: Meagan M. Costedio, M.D., Neil Hyman, M.D., Gary M. Mawe, Ph.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Serotonin (5-HT) is most commonly thought of as a neurotransmitter in the central nervous system. However, the predominant site of serotonin synthesis, storage, and release is the enterochromaffin cells of the intestinal mucosa. Within the intestinal mucosa, serotonin released from EC cells activates neural reflexes associated with intestinal secretion, motility, and sensation. Two important receptors for serotonin that are located in the neural circuitry of the intestines are the 5-HT3 and 5-HT4 receptors; these are the targets of drugs designed to treat gastrointestinal disorders. 5-HT3 receptor antagonists are used to treat nausea and emesis associated with chemotherapy and for functional disorders associated with diarrhea. 5-HT4 receptor agonists are used as promotility agents to promote gastric emptying and to alleviate constipation. Because of the importance of serotonin in normal gut function and sensation, a number of studies have investigated potential changes in mucosal serotonin signaling in pathologic conditions. Despite the inconsistencies in the current literature, changes in serotonin signaling have now been demonstrated in inflammatory bowel disease, irritable bowel syndrome, postinfectious irritable bowel syndrome, and idiopathic constipation. Emerging evidence has led to many contradictory theories regarding serotonin signaling and its roles in the pathology of gut disorders. This review summarizes the current medications affecting serotonin signaling and provides an overview of our current knowledge of the changes in serotonin that occur in pathologic conditions.
Literatur
1.
Bayliss, WM, Starling, EH 1899The movements and innervation of the small intestineJ Physiol2499143PubMed
2.
Bayliss, WM, Starling, EH 1900The movements and innervation of the small intestineJ Physiol26107138PubMed
3.
Bulbring, E, Crema, A 1959The release of 5-hydroxytryptamine in relation to pressure exerted on the intestinal mucosaJ Physiol1461828PubMed
4.
Erspamer, V, Vialli, M 1937Ricerche sul secreto delle cellule enterochromaffiniBoll Soc Med Chir Pavia51357363
5.
Whitaker-Azmitia, PM 1999The discovery of serotonin and its role in neuroscienceNeuropsychopharmacology212S8SPubMed
6.
Page, IH 1952The vascular action of natural serotonin, 5- and 7-hydroxytryptamine and tryptamineJ Pharmacol Exp Ther1055873PubMed
7.
Page, IH 1954Serotonin (5-hydroxytryptamine)Physiol Rev34563588PubMed
8.
Bulbring, E, Crema, A 1959The action of 5-hydroxytryptamine, 5-hydroxytryptophan and reserpine on intestinal peristalsis in anaesthetized guinea-pigsJ Physiol1462953PubMed
9.
Bulbring, E, Lin, RC 1958The effect of intraluminal application of 5-hydroxytryptamine and 5-hydroxytryptophan on peristalsis; the local production of 5-HT and its release in relation to intraluminal pressure and propulsive activityJ Physiol140381407PubMed
10.
Racke, K, Reimann, A, Schworer, H, Kilbinger, H 1996Regulation of 5-HT release from enterochromaffin cellsBehav Brain Res738387PubMed
11.
Racke, K, Schworer, H 1991Regulation of serotonin release from the intestinal mucosaPharmacol Res231325PubMed
12.
Gaddum, JH, Picarelli, ZP 1957Two kinds of tryptamine receptorBr J Pharmacol Chemother12323328PubMed
13.
Gershon, MD 1968Serotonin and the motility of the gastrointestinal tractGastroenterology54453456PubMed
14.
Kim, DY, Camilleri, M 2000Serotonin: A mediator of the brain-gut connectionAm J Gastroenterol9526982709PubMed
15.
Gershon, RR, Vlahov, D, Kelen, G, Conrad, B, Murphy, L 1995Review of accidents/injuries among emergency medical services workers in Baltimore, MarylandPrehospital Disaster Med101418PubMed
16.
Gershon, MD 2004Review article: Serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motilityAliment Pharmacol Ther20314PubMed
17.
Crowell, MD, Shetzline, MA, Moses, PL, Mawe, GM, Talley, NJ 2004Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal functionCurr Opin Investig Drugs55560PubMed
18.
Goyal, RK, Hirano, I 1996The enteric nervous systemN Engl J Med33411061115PubMed
19.
Bulbring, E, Gershon, MD 19675-hydroxytryptamine participation in the vagal inhibitory innervation of the stomachJ Physiol192823846PubMed
20.
Grundy, D 2002Towards a reduction of rectal pain?Neurogastroenterol Motil14217219PubMed
21.
Kirkup, AJ, Brunsden, AM, Grundy, D 2001Receptors and transmission in the brain-gut axis: Potential for novel therapies. I. Receptors on visceral afferentsAm J Physiol Gastrointest Liver Physiol280G787G794PubMed
22.
Fuller, RW, Wong, DT 1990Serotonin uptake and serotonin uptake inhibitionAnn N Y Acad Sci6006880PubMed
23.
Prada, M, Tranzer, JP, Pletscher, A 1972Storage of 5-hydroxytryptamine in human blood plateletsExperientia2813281329PubMed
24.
Gershon, MD 1991Serotonin: Its role and receptors in enteric neurotransmissionAdv Exp Med Biol294221230PubMed
25.
Wallis, DI, Stansfeld, CE, Nash, HL 1982Depolarizing responses recorded from nodose ganglion cells of the rabbit evoked by 5-hydroxytryptamine and other substancesNeuropharmacology213140PubMed
26.
Cash, BD, Chey, WD 2005Review article: The role of serotonergic agents in the treatment of patients with primary chronic constipationAliment Pharmacol Ther2210471060PubMed
27.
Hargreaves, AC, Lummis, SC, Taylor, CW 1994Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptorsMol Pharmacol4611201128PubMed
28.
Camilleri, M 2004Treating irritable bowel syndrome: Overview, perspective and future therapiesBr J Pharmacol14112371248PubMed
29.
Cremonini, F, Delgado-Aros, S, Camilleri, M 2003Efficacy of alosetron in irritable bowel syndrome: A meta-analysis of randomized controlled trialsNeurogastroenterol Motil157986PubMed
30.
Delvaux, M, Louvel, D, Mamet, JP, Campos-Oriola, R, Frexinos, J 1998Effect of alosetron on responses to colonic distension in patients with irritable bowel syndromeAliment Pharmacol Ther12849855PubMed
31.
Jones, RH, Holtmann, G, Rodrigo, L,  et al. 1999Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patientsAliment Pharmacol Ther1314191427PubMed
32.
Lembo, T, Wright, RA, Bagby, B,  et al. 2001Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndromeAm J Gastroenterol9626622670PubMed
33.
Olden, KW, Crowell, MD 2005CilansetronDrugs Today (Barc)41661666
34.
Brandt, LJ, Prather, CM, Quigley, EM, Schiller, LR, Schoenfeld, P, Talley, NJ 2005Systematic review on the management of chronic constipation in north americaAm J Gastroenterol100S5S21PubMed
35.
Callahan, MJ 2002Irritable bowel syndrome neuropharmacology. A review of approved and investigational compoundsJ Clin Gastroenterol35S58S67PubMed
36.
Camilleri, M 2001Review article: TegaserodAliment Pharmacol Ther15277289PubMed
37.
Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004; CD003960
38.
Kamm, MA, Muller-Lissner, S, Talley, NJ,  et al. 2005Tegaserod for the treatment of chronic constipation: A randomized, double-blind, placebo-controlled multinational studyAm J Gastroenterol100362372PubMed
39.
Muller-Lissner, SA, Fumagalli, I, Bardhan, KD,  et al. 2001Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipationAliment Pharmacol Ther1516551666PubMed
40.
Nyhlin, H, Bang, C, Elsborg, L,  et al. 2004A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndromeScand J Gastroenterol39119126PubMed
41.
Jailwala, J, Imperiale, TF, Kroenke, K 2000Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trialsAnn Intern Med133136147PubMed
42.
Kamm, MA 2002Review article: The complexity of drug development for irritable bowel syndromeAliment Pharmacol Ther16343351PubMed
43.
Ziegenhagen, DJ, Kruis, W 2004Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placeboJ Gastroenterol Hepatol19744749PubMed
44.
Bouras, EP, Camilleri, M, Burton, DD, Thomforde, G, McKinzie, S, Zinsmeister, AR 2001Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorderGastroenterology120354360PubMed
45.
Coremans, G, Kerstens, R, Pauw, M, Stevens, M 2003Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trialDigestion678289PubMed
46.
Schryver, AM, Andriesse, GI, Samsom, M, Smout, AJ, Gooszen, HG, Akkermans, LM 2002The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteersAliment Pharmacol Ther16603612PubMed
47.
Emmanuel, AV, Roy, AJ, Nicholls, TJ, Kamm, MA 2002Prucalopride, a systemic enterokinetic, for the treatment of constipationAliment Pharmacol Ther1613471356PubMed
48.
Sloots, CE, Poen, AC, Kerstens, R,  et al. 2002Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipationAliment Pharmacol Ther16759767PubMed
49.
Bharucha, AE, Camilleri, M, Haydock, S,  et al. 2000Effects of a serotonin 5-HT(4) receptor antagonist sb-207266 on gastrointestinal motor and sensory function in humansGut47667674PubMed
50.
Houghton, LA, Jackson, NA, Whorwell, PJ, Cooper, SM 19995-HT4 receptor antagonism in irritable bowel syndrome: Effect of sb-207266-a on rectal sensitivity and small bowel transitAliment Pharmacol Ther1314371444PubMed
51.
Sanger, GJ, Banner, SE, Smith, MI, Wardle, KA 1998Sb-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal modelsNeurogastroenterol Motil10271279PubMed
52.
Tonini, M, Ponti, F, Nucci, A, Crema, F 1999Review article: Cardiac adverse effects of gastrointestinal prokineticsAliment Pharmacol Ther1315851591PubMed
53.
Camilleri, M, McKinzie, S, Fox, J,  et al. 2004Effect of renzapride on transit in constipation-predominant irritable bowel syndromeClin Gastroenterol Hepatol2895904PubMed
54.
Galligan, JJ, Vanner, S 2005Basic and clinical pharmacology of new motility promoting agentsNeurogastroenterol Motil17643653PubMed
55.
Potet, F, Bouyssou, T, Escande, D, Baro, I 2001Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-a-gogo k(+) channelJ Pharmacol Exp Ther29910071012PubMed
56.
Carlsson, L, Amos, GJ, Andersson, B, Drews, L, Duker, G, Wadstedt, G 1997Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential?J Pharmacol Exp Ther282220227PubMed
57.
Mine, Y, Yoshikawa, T, Oku, S, Nagai, R, Yoshida, N, Hosoki, K 1997Comparison of effect of mosapride citrate and existing 5-HT4 receptor agonists on gastrointestinal motility in vivo and in vitro J Pharmacol Exp Ther28310001008PubMed
58.
Bertrand, PP, Kunze, WA, Furness, JB, Bornstein, JC 2000The terminals of myenteric intrinsic primary afferent neurons of the guinea-pig ileum are excited by 5-hydroxytryptamine acting at 5-hydroxytryptamine-3 receptorsNeuroscience101459469PubMed
59.
Galligan, JJ 1996Electrophysiological studies of 5-hydroxytryptamine receptors on enteric neuronsBehav Brain Res73199201PubMed
60.
Galligan, JJ 2002Pharmacology of synaptic transmission in the enteric nervous systemCurr Opin Pharmacol2623629PubMed
61.
Costall, B, Naylor, RJ 20045-HT3 receptorsCurr Drug Targets CNS Neurol Disord32737PubMed
62.
Talley, NJ, Phillips, SF, Haddad, A,  et al. 1990Gr 38032f (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy manDig Dis Sci35477480PubMed
63.
Ohe, MR, Hanson, RB, Camilleri, M 1994Serotonergic mediation of postprandial colonic tonic and phasic responses in humansGut35536541PubMed
64.
Camilleri, M, Chey, WY, Mayer, EA,  et al. 2001A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndromeArch Intern Med16117331740PubMed
65.
Camilleri, M, Northcutt, AR, Kong, S, Dukes, GE, McSorley, D, Mangel, AW 2000Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trialLancet35510351040PubMed
66.
Bockaert, J, Claeysen, S, Compan, V, Dumuis, A 20045-HT4 receptorsCurr Drug Targets CNS Neurol Disord33951PubMed
67.
Foxx-Orenstein, AE, Jin, JG, Grider, JR 19985-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsionAm J Physiol275G979G983PubMed
68.
Liu, M, Geddis, MS, Wen, Y, Setlik, W, Gershon, MD 2005Expression and function of 5-HT4 receptors in the mouse enteric nervous systemAm J Physiol Gastrointest Liver Physiol289G1148G1163PubMed
69.
Grider, JR 2006Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserodAm J Physiol Gastrointest Liver Physiol290G319G327PubMed
70.
Galligan, JJ, Pan, H, Messori, E 2003Signalling mechanism coupled to 5-hydroxytryptamine4 receptor-mediated facilitation of fast synaptic transmission in the guinea-pig ileum myenteric plexusNeurogastroenterol Motil15523529PubMed
71.
Pan, H, Galligan, JJ 19945-HT1a and 5-HT4 receptors mediate inhibition and facilitation of fast synaptic transmission in enteric neuronsAm J Physiol266G230G238PubMed
72.
Grider, JR, Foxx-Orenstein, AE, Jin, JG 19985-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestineGastroenterology115370380PubMed
73.
Jin, JG, Foxx-Orenstein, AE, Grider, JR 1999Propulsion in guinea pig colon induced by 5-hydroxytryptamine (HT) via 5-HT4 and 5-HT3 receptorsJ Pharmacol Exp Ther2889397PubMed
74.
Lyford, G, Foxx-Orenstein, A 2004Chronic intestinal pseudoobstructionCurr Treat Options Gastroenterol7317325PubMed
75.
Ferriman, A 2000UK licence for cisapride suspendedBMJ321259PubMed
76.
Linden, DR, Chen, JX, Gershon, MD, Sharkey, KA, Mawe, GM 2003Serotonin availability is increased in mucosa of guinea pigs with tnbs-induced colitisAm J Physiol Gastrointest Liver Physiol285G207G216PubMed
77.
O’Hara, JR, Ho, W, Linden, DR, Mawe, GM, Sharkey, KA 2004Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitisAm J Physiol Gastrointest Liver Physiol287G998G1007PubMed
78.
Linden, DR, Foley, KF, McQuoid, C, Simpson, J, Sharkey, KA, Mawe, GM 2005Serotonin transporter function and expression are reduced in mice with TNBS-induced colitisNeurogastroenterol Motil1756574PubMed
79.
Wheatcroft, J, Wakelin, D, Smith, A, Mahoney, CR, Mawe, G, Spiller, R 2005Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunctionNeurogastroenterol Motil17863870PubMed
80.
O’Hara, JR, Skinn, AC, MacNaughton, WK, Sherman, PM, Sharkey, KA 2006Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colonCell Microbiol8646660PubMed
81.
Coates, MD, Mahoney, CR, Linden, DR,  et al. 2004Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndromeGastroenterology12616571664PubMed
82.
Ahonen, A, Kyosola, K, Penttila, O 1976Enterochromaffin cells in macrophages in ulcerative colitis and irritable colonAnn Clin Res817PubMed
83.
Magro, F, Vieira-Coelho, MA, Fraga, S,  et al. 2002Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel diseaseDig Dis Sci47216224PubMed
84.
El-Salhy, M, Danielsson, A, Stenling, R, Grimelius, L 1997Colonic endocrine cells in inflammatory bowel diseaseJ Intern Med242413419PubMed
85.
Bearcroft, CP, Perrett, D, Farthing, MJ 1998Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot studyGut424246PubMedCrossRef
86.
Miwa, J, Echizen, H, Matsueda, K, Umeda, N 2001Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habitsDigestion63188194PubMed
87.
Atkinson, W, Lockhart, S, Whorwell, PJ, Keevil, B, Houghton, LA 2006Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndromeGastroenterology1303443PubMed
88.
Dunlop, SP, Coleman, NS, Blackshaw, E,  et al. 2005Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndromeClin Gastroenterol Hepatol3349357PubMed
89.
Spiller, RC, Jenkins, D, Thornley, JP,  et al. 2000Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndromeGut47804811PubMed
90.
Dunlop, SP, Jenkins, D, Neal, KR, Spiller, RC 2003Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBSGastroenterology12516511659PubMed
91.
Lincoln, J, Crowe, R, Kamm, MA, Burnstock, G, Lennard-Jones, JE 1990Serotonin and 5-hydroxyindoleacetic acid are increased in the sigmoid colon in severe idiopathic constipationGastroenterology9812191225PubMed
92.
Zhao, R, Baig, MK, Wexner, SD,  et al. 2000Enterochromaffin and serotonin cells are abnormal for patients with colonic inertiaDis Colon Rectum43858863PubMed
93.
Simren, M, Axelsson, J, Gillberg, R, Abrahamsson, H, Svedlund, J, Bjornsson, ES 2002Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factorsAm J Gastroenterol97389396PubMed
94.
Neal, KR, Hebden, J, Spiller, R 1997Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patientsBMJ314779782PubMed
95.
Drossman, DA, Whitehead, WE, Camilleri, M 1997Irritable bowel syndrome: A technical review for practice guideline developmentGastroenterology11221202137PubMed
96.
Chadwick, VS, Chen, W, Shu, D,  et al. 2002Activation of the mucosal immune system in irritable bowel syndromeGastroenterology12217781783PubMed
97.
Tornblom, H, Lindberg, G, Nyberg, B, Veress, B 2002Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndromeGastroenterology12319721979PubMed
98.
Mertz, H, Morgan, V, Tanner, G,  et al. 2000Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distentionGastroenterology118842848PubMed
99.
Locke, GR,3rd, Zinsmeister, AR, Talley, NJ, Fett, SL, Melton, LJ,3rd 2000Familial association in adults with functional gastrointestinal disordersMayo Clin Proc75907912PubMedCrossRef
100.
Nobaek, S, Johansson, ML, Molin, G, Ahrne, S, Jeppsson, B 2000Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndromeAm J Gastroenterol9512311238PubMed
101.
Gershon, MD 2005Nerves, reflexes, and the enteric nervous system: Pathogenesis of the irritable bowel syndromeJ Clin Gastroenterol39S184S193PubMed
102.
Chen, JJ, Li, Z, Pan, H,  et al. 2001Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transportersJ Neurosci2163486361PubMed
103.
Coates, MD, Johnson, AC, Greenwood-Van Meerveld, B, Mawe, GM 2006Effects of serotonin transporter inhibition on gastrointestinal motility and colonic sensitivity in the mouseNeurogastroenterol Motil18464471PubMed
104.
Camilleri, M, Mayer, EA, Drossman, DA,  et al. 1999Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonistAliment Pharmacol Ther1311491159PubMed
105.
Ponti, F, Tonini, M 2001Irritable bowel syndrome: New agents targeting serotonin receptor subtypesDrugs61317332PubMed
106.
Knowles, CH, Scott, M, Lunniss, PJ 1999Outcome of colectomy for slow transit constipationAnn Surg230627638PubMed
107.
Sonnenberg, A, Koch, TR 1989Epidemiology of constipation in the United StatesDis Colon Rectum3218PubMed
108.
Voderholzer, WA, Schatke, W, Muhldorfer, BE, Klauser, AG, Birkner, B, Muller-Lissner, SA 1997Clinical response to dietary fiber treatment of chronic constipationAm J Gastroenterol929598PubMed
109.
He, CL, Burgart, L, Wang, L,  et al. 2000Decreased interstitial cell of Cajal volume in patients with slow-transit constipationGastroenterology1181421PubMed
110.
Tong, WD, Liu, BH, Zhang, LY, Zhang, SB, Lei, Y 2004Decreased interstitial cells of Cajal in the sigmoid colon of patients with slow transit constipationInt J Colorectal Dis19467473PubMed
111.
Facer, P, Knowles, CH, Thomas, PK, Tam, PK, Williams, NS, Anand, P 2001Decreased tyrosine kinase C expression may reflect developmental abnormalities in Hirschsprung’s disease and idiopathic slow-transit constipationBr J Surg88545552PubMed
112.
Knowles, CH, Gayther, SA, Scott, M,  et al. 2000Idiopathic slow-transit constipation is not associated with mutations of the ret proto-oncogene or GDNFDis Colon Rectum43851857PubMed
113.
Altomare, DF, Portincasa, P, Rinaldi, M,  et al. 1999Slow-transit constipation: Solitary symptom of a systemic gastrointestinal diseaseDis Colon Rectum42231240PubMed
114.
Xiao, ZL, Pricolo, V, Biancani, P, Behar, J 2005Role of progesterone signaling in the regulation of g-protein levels in female chronic constipationGastroenterology128667675PubMed
115.
Bueno, L, Fioramonti, J 1988Action of opiates on gastrointestinal functionBaillieres Clin Gastroenterol2123139PubMed
116.
Fotherby, KJ, Hunter, JO 1987Idiopathic slow-transit constipation: Whole gut transit times, measured by a new simplified method, are not shortened by opioid antagonistsAliment Pharmacol Ther1331338PubMedCrossRef
117.
Sonsino, E, Mouy, R, Foucaud, P,  et al. 1984Intestinal pseudo-obstruction related to cytomegalovirus infection of myenteric plexusN Engl J Med311196197PubMed
118.
Sykes, NP 1991Oral naloxone in opioid-associated constipationLancet3371475PubMed
119.
Vassallo, M, Camilleri, M, Caron, BL, Low, PA 1991Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosisGastroenterology100252258PubMed
120.
Knowles, CH, Martin, JE 2000Slow transit constipation: A model of human gut dysmotility. Review of possible aetiologiesNeurogastroenterol Motil12181196PubMed
121.
Zhao, RH, Baig, MK, Thaler, KJ,  et al. 2003Reduced expression of serotonin receptor(s) in the left colon of patients with colonic inertiaDis Colon Rectum468186PubMed
122.
Johanson, JF, Wald, A, Tougas, G,  et al. 2004Effect of tegaserod in chronic constipation: A randomized, double-blind, controlled trialClin Gastroenterol Hepatol2796805PubMed
123.
Piccirillo, MF, Reissman, P, Wexner, SD 1995Colectomy as treatment for constipation in selected patientsBr J Surg82898901PubMed
124.
FitzHarris, GP, Garcia-Aguilar, J, Parker, SC,  et al. 2003Quality of life after subtotal colectomy for slow-transit constipation: Both quality and quantity countDis Colon Rectum46433440PubMed
125.
Saunders, MD, Kimmey, MB 2005Systematic review: Acute colonic pseudo-obstructionAliment Pharmacol Ther22917925PubMed
126.
Giorgio, R, Barbara, G, Stanghellini, V,  et al. 2001Review article: The pharmacological treatment of acute colonic pseudo-obstructionAliment Pharmacol Ther1517171727PubMed
127.
Paran, H, Silverberg, D, Mayo, A, Shwartz, I, Neufeld, D, Freund, U 2000Treatment of acute colonic pseudo-obstruction with neostigmineJ Am Coll Surg190315318PubMed
128.
Ponec, RJ, Saunders, MD, Kimmey, MB 1999Neostigmine for the treatment of acute colonic pseudo-obstructionN Engl J Med341137141PubMed
129.
Stephenson, BM, Morgan, AR, Salaman, JR, Wheeler, MH 1995Ogilvie’s syndrome: A new approach to an old problemDis Colon Rectum38424427PubMed
130.
Trevisani, GT, Hyman, NH, Church, JM 2000Neostigmine: Safe and effective treatment for acute colonic pseudo-obstructionDis Colon Rectum43599603PubMed
131.
MacColl, C, MacCannell, KL, Baylis, B, Lee, SS 1990Treatment of acute colonic pseudo-obstruction (Ogilvie’s syndrome) with cisaprideGastroenterology98773776PubMed
132.
Pelckmans, PA, Michielsen, PP, Jorens, PG, Maercke, YM 1990Cisapride in Ogilvie’s syndromeGastroenterology9911945PubMed
Metadaten
Titel
Serotonin and Its Role in Colonic Function and in Gastrointestinal Disorders
verfasst von
Meagan M. Costedio, M.D.
Neil Hyman, M.D.
Gary M. Mawe, Ph.D.
Publikationsdatum
01.03.2007
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 3/2007
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0763-3

Weitere Artikel der Ausgabe 3/2007

Diseases of the Colon & Rectum 3/2007 Zur Ausgabe

OriginalPaper

Bacterial Translocation May Influence the Long-Term Survival in Colorectal Cancer Patients

OriginalPaper

Selected Abstracts

OriginalPaper

Goblet Cell Carcinoid Tumors (Adenocarcinoid) of the Appendix

Erratum

Effect of Aging on Anorectal and Pelvic Floor Functions in Females

OriginalPaper

Female Bowel Function: The Real Story

Technical Note

Assistance of Colorectal Stent Insertion by Sphincterotome

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.